Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. (15th August 2017)

• Record Type: Journal Article
• Authors: Fanaroff, Alexander C; Hasselblad, Vic; Roe, Matthew T; Bhatt, Deepak L; James, Stefan K; Steg, Ph Gabriel; Gibson, C Michael; Ohman, E Magnus
• Is Part Of: International journal of cardiology. Volume 241(2017)
• Page Start: 87
• Page End: 96
• Publication Date: 2017-08-15
• Subjects: Acute coronary syndrome -- Acute myocardial infarction -- Antiplatelet agents, antithrombotic agents -- Network meta-analysis; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2017.03.046
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Nine oral antithrombotic medications currently available in the United States and Europe have been studied in clinical trials for secondary prevention of cardiac events following acute coronary syndrome (ACS). Few combinations of these medications have been directly compared, and studies have used multiple different comparator regimens. Methods: We performed a systematic review and network meta-analysis of randomized controlled trials evaluating one or more available oral antithrombotic therapies in patients with ACS or prior myocardial infarction (MI). Co-primary outcomes were all-cause and cardiovascular mortality compared with imputed placebo and aspirin monotherapy. Results: Forty-seven studies (196, 057 subjects) met inclusion criteria and were included in the systematic review. Almost all studies tested either aspirin monotherapy compared with placebo or a combination of antithrombotic agents that included aspirin. Nearly all regimens reduced all-cause and cardiovascular mortality compared with imputed placebo. However, compared with imputed aspirin monotherapy, only combination therapy with aspirin plus ticagrelor was associated with lower cardiovascular mortality (OR 0.80, 95% CI 0.68–0.93), and triple therapy with aspirin, clopidogrel, and very low dose rivaroxaban was associated with lower all-cause mortality (OR 0.67, 95% CI 0.49–0.90). Major bleeding was increased 45–95% with dual antithrombotic therapy, and 2–6-fold with triple therapy. Conclusion: Few combinations of antithrombotic therapy were associated with a reduction in mortality compared with aspirin monotherapy, highlighting the difficulty in clinical interpretation of composite ischemic endpoints. Future studies may need to focus on limiting the number of antithrombotic therapies tested in combination to best balance ischemic event reduction and bleeding.